THE NCI TRANSLATIONAL RESEARCH PROGRAM published the full list of FY2016 Specialized Programs of Research Excellence grantees. The SPORE program uses the P50 grant funding mechanism to promote collaborative, interdisciplinary, translational cancer multi-project research. SPOREs are primarily focused on organ site disease, but also on themes that cut across organ sites. Including the 2016 grantees,... […]
WILLIAM KAELIN, Peter Ratcliffe, and Gregg Semenza received the 2016 Lasker Award for basic medical research. Ralf Bartenschlager, Charles Rice, and Michael Sofia received the award for clinical research, and Bruce Alberts for special achievement. The awards, which carry an honorarium of $250,000 for each category, will be presented on Friday, Sept. 23, in New... […]
ERIC FEARON was named director of the University of Michigan Comprehensive Cancer Center.
THE EUROPEAN COMMISSION issued a marketing authorization for lenvatinib (Kisplyx) in combination with everolimus for the treatment of adult patients with advanced renal cell carcinoma following one prior vascular endothelial growth factor (VEGF)-targeted therapy. Lenvatinib was granted an accelerated assessment by the European Medicines Agency in October 2015. Marketing authorization follows the evaluation of results... […]
THE TERRY FOX FOUNDATION in partnership with the Canadian Institutes of Health Research has awarded $27.3 million in new funding to six Canadian research teams to engineer precision medicines for patients whose cancer has relapsed or for whom current treatments are ineffective or non-existent. The Terry Fox Research Institute teams are conducting research into brain,... […]
FDA said it has taken action against 55 tobacco retailers by issuing the first warning letters for selling newly regulated tobacco products, such as e-cigarettes, e-liquids and cigars, to minors. These actions come about a month after FDA began enforcing new federal regulations making it illegal nationwide to sell e-cigarettes, cigars, hookah tobacco, and other... […]
FDA has modified the dosage regimen for nivolumab (Opdivo), sponsored by Bristol-Myers Squibb Co., for the currently approved indications for renal cell carcinoma, metastatic melanoma, and non-small cell lung cancer. The currently approved recommended dosage regimens were modified to 240 mg intravenously (IV) every two weeks. jQuery(document).ready(function(){ jQuery('.people-thumb + p > span.has-red-100-color, .people-thumb + p... […]
THOMAS IMPERIALE, investigator at the Regenstrief Institute, was named the inaugural Lawrence Lumeng Professor in Gastroenterology and Hepatology at Indiana University School of Medicine. Imperiale is a health services researcher and a clinical gastroenterologist. His research focuses on developing and testing screening strategies for colorectal cancer based on risk factors. In addition to the IU... […]
ASHANI WEERATNA, associate professor and program leader in the Tumor Microenvironment and Metastasis Program, was named the Ira Brind Associate Professor at the Wistar Institute. Weeraratna’s primary research focus is how melanoma metastasizes and how changes in the tumor microenvironment might initiate the disease’s spread or make it resistant to treatment. She is also a... […]
LEVI GARRAWAY was named senior vice president, Global Development & Medical Affairs, for Eli Lilly and Co.‘s Oncology business. He will succeed Richard Gaynor, who is retiring, on Jan. 1, 2017. Garraway is an associate professor of medicine in the Department of Medical Oncology at the Dana-Farber Cancer Institute and Harvard Medical School, an associate... […]
